Lupin launches generic anti-diabetic tablets in US

Pharma major Lupin has launched its generic anti-diabetic medicine in the United States. The medicine is dapagliflozin and metformin hydrochloride extended-release tablets. The US Food and Drug Administration approved the drug. Lupin's product is bioequivalent to Xigduo XR. This launch offers a new treatment option for diabetic patients in the US.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hzWucXo
via IFTTT